Mbx Biosciences, INC

MBX Biosciences announced its second quarter 2026 financial results, highlighting progress in its hypoparathyroidism and obesity drug development programs, with a strong cash runway into 2029.

MBX Biosciences announces the departure of CEO Kent P. Hawryluk and the appointment of Steven Hoerter as the new President and CEO, effective July 13, 2026.

MBX Biosciences announced one-year clinical data for canvuparatide in chronic hypoparathyroidism, showing sustained efficacy and safety as it prepares for a Phase 3 trial.

MBX Biosciences stockholders re-elected two Class II directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

MBX Biosciences announced positive initial Phase 1 data for MBX 4291, a potential once-monthly obesity treatment, and nominated MBX 5765 as a new amycretin prodrug candidate.

MBX Biosciences announced Q1 2026 financial results, highlighting progress in its canvuparatide and MBX 4291 pipelines, with strong cash reserves extending operational runway into 2029.

MBX Biosciences reports a widening net loss in Q2 2026 driven by increased research and development expenses, though the company maintains a substantial cash reserve and advances its pipeline.

MBX Biosciences reports a net loss of $23.5 million for Q1 2026, with decreased R&D expenses but higher G&A costs, while maintaining a substantial cash reserve of $440 million.

MBX Biosciences reported increased net losses for Q3 2025 but maintains strong liquidity to fund operations into 2029, driven by a recent $187.4 million public offering and positive clinical trial progress.

MBX Biosciences reports increased R&D spend and net losses in Q2 2025, while advancing its lead drug candidates and extending its cash runway into mid-2027.

MBX Biosciences reports increased R&D spending and a net loss for Q1 2025, while advancing its clinical programs for endocrine and metabolic disorders.

MBX Biosciences reports a net loss of $18.1 million for the third quarter of 2024, alongside a significant increase in cash and marketable securities following its IPO.

MBX Biosciences, Inc. reported significant progress in its clinical pipeline, including positive Phase 2 results for canvuparatide in hypoparathyroidism and advancement of obesity and post-bariatric hypoglycemia candidates, alongside increased net losses and a strong cash position to fund operations into 2029.

MBX Biosciences' 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical-stage precision peptide therapies for endocrine and metabolic disorders.

Salomon Azoulay, Chief Medical Officer of MBX Biosciences, Inc., sold 370 shares of common stock on August 4, 2026 for $65.77 per share.

John W Smither, Chief Financial Officer of MBX Biosciences, Inc., reported multiple transactions in common stock on August 3, 2026.

Steven L. Hoerter, President and CEO and a Director of MBX Biosciences, Inc., reported multiple transactions in common stock on August 3, 2026.

Director Edward T. Mathers was granted 12,500 stock options in MBX Biosciences, Inc. as part of his compensation package.

Director Ora H. Pescovitz was granted 12,500 stock options in MBX Biosciences, Inc. as part of standard director compensation.

Director Patrick J. Heron was granted 12,500 stock options in MBX Biosciences, Inc. as part of his non-employee director compensation.

MBX Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026, to elect directors and ratify auditors.

MBX Biosciences announces its 2025 Annual Meeting of Stockholders to be held on June 5, 2025, featuring the election of directors and ratification of the company's independent auditor.

MBX Biosciences will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.

MBX Biosciences, Inc. increased its public offering by 1,274,263 common stock shares, including over-allotment options, through a Rule 462(b) filing.

MBX Biosciences announced a public offering of 10 million common shares following positive topline Phase 2 clinical trial results for its lead candidate, canvuparatide, for chronic hypoparathyroidism.

MBX Biosciences has filed a registration statement to increase its common stock offering by 1,955,000 shares, including an underwriter option, representing no more than 20% of the initial offering price.

MBX Biosciences, a clinical-stage biopharmaceutical company, files an amendment to its S-1 registration statement for a proposed initial public offering of 8,500,000 shares of common stock, aiming to raise approximately $114.8 million for continued development of its precision peptide therapies.

MBX Biosciences advances its IPO plans with an amendment, highlighting clinical trial progress and financial details.

MBX Biosciences, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of its precision peptide therapies for endocrine and metabolic disorders.

Frazier Life Sciences entities and individuals have filed an amendment to Schedule 13D, reporting changes in beneficial ownership of MBX Biosciences, Inc. common stock.

OrbiMed Advisors and its affiliates have reduced their beneficial ownership in MBX Biosciences, Inc. to 7.7% due to share sales and an increase in outstanding shares.

New Enterprise Associates 17 and its affiliates have reported a decrease in their beneficial ownership of MBX Biosciences, Inc. common stock to 8.1% due to an increase in outstanding shares.

OrbiMed Advisors and its affiliates reported a decrease in their beneficial ownership of MBX Biosciences, Inc. common stock to 9.0% due to an increase in the issuer's outstanding shares.

Norwest Venture Partners and its affiliates reported a decrease in their beneficial ownership of MBX Biosciences common stock to 4.8% following the company's recent public offering.

Frazier Life Sciences and affiliated entities have increased their beneficial ownership in MBX Biosciences, Inc., with a recent purchase of 666,666 shares at $18.00 per share.

Deep Track Capital, LP, along with affiliated entities, has reported beneficial ownership of 3.64% of MBX Biosciences, Inc. common stock as of June 30, 2026.

Wellington Management Group LLP and its affiliates have reported a significant beneficial ownership stake of 10.5% in MBX Biosciences, as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.2% of MBX Biosciences Inc.'s common stock as of June 30, 2026.

Paradigm BioCapital Advisors LP and associated entities have reported a 5.2% beneficial ownership stake in MBX Biosciences, Inc. as of June 16, 2026.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.2% of MBX Biosciences Inc. common stock as of March 31, 2026.

Wellington Management Group LLP and its affiliates have disclosed a 7.5% beneficial ownership stake in MBX Biosciences' Common Stock.